Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Allahyari A, Ehsanpour A, Ansarinejad N, Mehrzad V, et al. Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer 2022;22:960.
PMID: 36071409


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016